{"protocolSection": {"identificationModule": {"nctId": "NCT02551874", "orgStudyIdInfo": {"id": "CV181-369"}, "secondaryIdInfos": [{"id": "2015-001702-33", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin", "officialTitle": "A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy"}, "statusModule": {"statusVerifiedDate": "2018-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-10-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-05-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-11-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-15", "studyFirstSubmitQcDate": "2015-09-15", "studyFirstPostDateStruct": {"date": "2015-09-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-05-07", "resultsFirstSubmitQcDate": "2018-08-20", "resultsFirstPostDateStruct": {"date": "2018-09-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-11-20", "lastUpdatePostDateStruct": {"date": "2018-12-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.", "detailedDescription": "CV181-369; A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 650, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin/Dapagliflozin/Metformin", "type": "EXPERIMENTAL", "description": "Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin", "interventionNames": ["Drug: Saxagliptin, Onglyza", "Drug: Dapagliflozin, Farxiga", "Drug: Metformin"]}, {"label": "Insulin Glargine, Lantos/Metformin", "type": "ACTIVE_COMPARATOR", "description": "Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.", "interventionNames": ["Drug: Glargine insulin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin, Onglyza", "description": "Tablets, Oral, 5mg , Once daily, 24 weeks", "armGroupLabels": ["Saxagliptin/Dapagliflozin/Metformin"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Dapagliflozin, Farxiga", "description": "Tablets, Oral, 10mg , Once daily, 24 weeks", "armGroupLabels": ["Saxagliptin/Dapagliflozin/Metformin"], "otherNames": ["BMS-512148"]}, {"type": "DRUG", "name": "Glargine insulin", "description": "100 Units/ml solution for injection in a prefilled SoloStar pen", "armGroupLabels": ["Insulin Glargine, Lantos/Metformin"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "Metformin", "description": "Tablets, Oral, \u2265 1500mg/\u2264 2500mg, Once daily, 24 weeks", "armGroupLabels": ["Saxagliptin/Dapagliflozin/Metformin"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in HbA1c at Week 24", "description": "To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Total Body Weight at Week 24", "description": "To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Subjects With Confirmed Hypoglycaemia at Week 24", "description": "Hypoglycemia defined as plasma glucose \u226470 mg/dL (3.9 mmol/L)", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24", "description": "To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24", "description": "To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in the Mean Value of 24-hour Glucose at Week 2", "description": "Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.", "timeFrame": "Baseline and Week 2"}]}, "eligibilityModule": {"eligibilityCriteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* At least 18 years of age at screening\n* HbA1c \u2265 8% and \u2264 12% at screening\n* Fasting plasma glucose (FPG) \u2264 270 mg/dL (15mmol/L)\n* Stable dose metformin \u2265 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks\n* estimated glomerular filtration rate (eGFR) \\&lt; 60 ml/ml/1.73m2\n* Body Mass Index \u2264 45.0 kg/m2\n\nExclusion Criteria:\n\n* Clinical diagnosis of Type 1 diabetes\n* History of ketoacidosis\n* Renal, hepatic or pancreatic disease\n* Impairment of renal function (defined as creatinine clearance \\[CrCl\\] \\< 60 mL/min\n* Cardiovascular or vascular diseases identified within 3 months of participationImpairment of renal function (defined as creatinine clearance \\[CrCl\\] \\< 60 mL/min", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "120 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33144", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33709", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Norcross", "state": "Georgia", "zip": "30071", "country": "United States", "geoPoint": {"lat": 33.94121, "lon": -84.21353}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Lexington", "state": "Kentucky", "zip": "40502", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Research Site", "city": "Quincy", "state": "Massachusetts", "zip": "02169", "country": "United States", "geoPoint": {"lat": 42.25288, "lon": -71.00227}}, {"facility": "Research Site", "city": "Beavercreek", "state": "Ohio", "zip": "45432", "country": "United States", "geoPoint": {"lat": 39.70923, "lon": -84.06327}}, {"facility": "Research Site", "city": "Norman", "state": "Oklahoma", "zip": "73069", "country": "United States", "geoPoint": {"lat": 35.22257, "lon": -97.43948}}, {"facility": "Research Site", "city": "Barto", "state": "Pennsylvania", "zip": "19504", "country": "United States", "geoPoint": {"lat": 40.39121, "lon": -75.61019}}, {"facility": "Research Site", "city": "Columbia", "state": "South Carolina", "zip": "29204", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Research Site", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Research Site", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77004", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Mesquite", "state": "Texas", "zip": "74194", "country": "United States", "geoPoint": {"lat": 32.7668, "lon": -96.59916}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78230", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78258", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Bountiful", "state": "Utah", "zip": "84010", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"facility": "Research Site", "city": "Karlovy Vary", "zip": "360 01", "country": "Czechia", "geoPoint": {"lat": 50.23271, "lon": 12.87117}}, {"facility": "Research Site", "city": "Olomouc", "zip": "772 00", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Research Site", "city": "Koebenhavn", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Research Site", "city": "Budapest", "zip": "1032", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1097", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1171", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Guadalajara", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Mexico", "zip": "03800", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Zapopan, Jalisco", "zip": "45200", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Research Site", "city": "Lodz", "zip": "92-003", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "Nowy Duninow", "zip": "09-505", "country": "Poland", "geoPoint": {"lat": 52.58271, "lon": 19.47996}}, {"facility": "Research Site", "city": "Sochaczew", "zip": "96-500", "country": "Poland", "geoPoint": {"lat": 52.22944, "lon": 20.23838}}, {"facility": "Research Site", "city": "Craiova", "zip": "200349", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Research Site", "city": "Ploiesti", "zip": "100018", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "Research Site", "city": "Timisoara", "zip": "300125", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Research Site", "city": "Timi\u0219oara", "zip": "300456", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Research Site", "city": "Lenasia", "zip": "1827", "country": "South Africa", "geoPoint": {"lat": -26.32052, "lon": 27.83564}}, {"facility": "Research Site", "city": "La Coru\u00f1a", "zip": "15006", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Research Site", "city": "Uddevalla", "zip": "451 80", "country": "Sweden", "geoPoint": {"lat": 58.34784, "lon": 11.9424}}]}, "referencesModule": {"references": [{"pmid": "31167892", "type": "DERIVED", "citation": "Vilsboll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care. 2019 Aug;42(8):1464-1472. doi: 10.2337/dc18-1988. Epub 2019 Jun 4."}], "seeAlsoLinks": [{"label": "cv181-369 SAP redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4129&filename=cv181-369_SAP_redacted.pdf"}, {"label": "cv181-369 CSP redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4129&filename=cv181-369_CSP_redacted.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study duration was up to 56 weeks, consisting of a 2-week screening period, 2-week lead-in period, 24-week short-term treatment period, and 28-week long-term treatment period.", "recruitmentDetails": "This study was conducted at 112 centers in 11 countries from 20 Oct 2015 to 10 Nov 2017. There were 2 data cut-offs for this study: 8 May 2017 for analyses of the short-term study period (after 24 weeks of open-label treatment) and 10 Nov 2017 for analyses of the short-term plus long-term study period (after 52 weeks of open-label treatment).", "groups": [{"id": "FG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 milligrams (mg) and saxagliptin 5 mg, administered orally once daily (QD) in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without sulfonylurea (SU) throughout the study."}, {"id": "FG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kilogram (kg) body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "324"}, {"groupId": "FG001", "numSubjects": "326"}]}, {"type": "Received Treatment in Short-term Study", "achievements": [{"groupId": "FG000", "numSubjects": "324"}, {"groupId": "FG001", "numSubjects": "319"}]}, {"type": "Entered Long-term Study", "achievements": [{"groupId": "FG000", "numSubjects": "306"}, {"groupId": "FG001", "numSubjects": "294"}]}, {"type": "Received Treatment in Long-term Study", "achievements": [{"groupId": "FG000", "numSubjects": "295"}, {"groupId": "FG001", "numSubjects": "284"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "296"}, {"groupId": "FG001", "numSubjects": "287"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "39"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Reason not reported", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Did not receive randomized treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Did not enter long-term study", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "25"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "BG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "324"}, {"groupId": "BG001", "value": "319"}, {"groupId": "BG002", "value": "643"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.7", "spread": "9.52"}, {"groupId": "BG001", "value": "55.3", "spread": "9.63"}, {"groupId": "BG002", "value": "55.5", "spread": "9.57"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "148"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "296"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "176"}, {"groupId": "BG001", "value": "171"}, {"groupId": "BG002", "value": "347"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "American Indian Or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "18"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": "Black Or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "63"}]}]}, {"title": "Native Hawaiian Or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "263"}, {"groupId": "BG001", "value": "254"}, {"groupId": "BG002", "value": "517"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline in HbA1c at Week 24", "description": "To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "populationDescription": "The randomized subjects data set consisted of all randomized subjects who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% HbA1c", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}, {"groupId": "OG001", "value": "312"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.67", "lowerLimit": "-1.79", "upperLimit": "-1.55"}, {"groupId": "OG001", "value": "-1.54", "lowerLimit": "-1.66", "upperLimit": "-1.42"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Noninferiority was defined by upper bound of 95% CI \\<0.3%", "pValue": "0.118", "pValueComment": "Superiority", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted for treatment, baseline HbA1c, randomization stratification factor, visit, treatment-by-visit, and baseline HbA1c-by-visit.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.30", "ciUpperLimit": "0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.085"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Total Body Weight at Week 24", "description": "To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment", "populationDescription": "The number of participants is the number of subjects in the randomized subject data set with non-missing baseline assessments and at least one post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}, {"groupId": "OG001", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "lowerLimit": "-1.89", "upperLimit": "-1.11"}, {"groupId": "OG001", "value": "2.14", "lowerLimit": "1.75", "upperLimit": "2.54"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted for treatment, baseline body weight, randomization stratification factor, visit, treatment-by-visit, and baseline body weight-by-visit.", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.20", "ciUpperLimit": "-3.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.282"}]}, {"type": "SECONDARY", "title": "Percentage of Subjects With Confirmed Hypoglycaemia at Week 24", "description": "Hypoglycemia defined as plasma glucose \u226470 mg/dL (3.9 mmol/L)", "populationDescription": "The randomized subject data set consisted of all randomized subjects who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Adjusted % Participants", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "324"}, {"groupId": "OG001", "value": "319"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.3", "lowerLimit": "17.03", "upperLimit": "26.22"}, {"groupId": "OG001", "value": "38.4", "lowerLimit": "32.94", "upperLimit": "44.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Adjusted for baseline HbA1c and randomization stratification factor (background medication of metformin with or without SU).", "paramType": "Odds Ratio (OR)", "paramValue": "0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.30", "ciUpperLimit": "0.62"}]}, {"type": "SECONDARY", "title": "Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24", "description": "To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "populationDescription": "The randomized subject data set consisted of all randomized subjects who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Adjusted % Participants", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "324"}, {"groupId": "OG001", "value": "319"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.9", "lowerLimit": "16.69", "upperLimit": "25.83"}, {"groupId": "OG001", "value": "13.1", "lowerLimit": "9.72", "upperLimit": "17.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.008", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.16", "ciUpperLimit": "2.67"}]}, {"type": "SECONDARY", "title": "Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24", "description": "To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.", "populationDescription": "The randomized subject data set consisted of all randomized subjects who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Adjusted % Participants", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "324"}, {"groupId": "OG001", "value": "319"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.2", "lowerLimit": "28.00", "upperLimit": "38.79"}, {"groupId": "OG001", "value": "33.5", "lowerLimit": "28.28", "upperLimit": "39.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Noninferiority was defined by lower bound of 95% CI \\>-10%.", "paramType": "Adjusted Percent Difference", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.42", "ciUpperLimit": "6.54"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Mean Value of 24-hour Glucose at Week 2", "description": "Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.", "populationDescription": "The randomized subject data set consisted of all randomized subjects who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/deciliter (dL)", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}, {"id": "OG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "133"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-48.53", "lowerLimit": "-53.47", "upperLimit": "-43.59"}, {"groupId": "OG001", "value": "-28.54", "lowerLimit": "-33.47", "upperLimit": "-23.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Noninferiority was defined by upper bound of 95% CI \\<12 mg/dL.", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Adjusted for treatment, baseline measurement, randomization stratification factor, visit, treatment-by-visit, and baseline-by-visit.", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.98", "ciUpperLimit": "-13.00", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.55"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From baseline (Day 1) up to Week 52 (24-week short-term treatment period + 28-week long-term treatment period).", "description": "Adverse event (AE) data is reported for the treated subject data set, and included AEs with an onset date on or after the date of first dose of short-term study treatment and up to and including 30 days following the date of last dose of short-term + long-term study treatment.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin + Saxagliptin + Metformin", "description": "Subjects received dapagliflozin 10 mg and saxagliptin 5 mg, administered orally QD in the morning for the 52-week treatment period (24-week short-term period and 28-week long term period).\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study.", "deathsNumAffected": 2, "deathsNumAtRisk": 324, "seriousNumAffected": 20, "seriousNumAtRisk": 324, "otherNumAffected": 55, "otherNumAtRisk": 324}, {"id": "EG001", "title": "Titrated Insulin + Metformin", "description": "Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investigator instructions and training. All subjects started with an initial dose of 0.2 units/kg body weight or at least 10 units of insulin per day. Subjects self-titrated the dose of insulin glargine over the first 8 weeks of the study based on daily glucose monitoring. The investigator had the discretion to modify insulin dose based on his/her assessment between Week 8 and Week 12 with the goal to reach an acceptable and stable insulin dose by Week 12.\n\nSubjects continued to receive their stable dose of metformin with or without SU throughout the study.", "deathsNumAffected": 0, "deathsNumAtRisk": 319, "seriousNumAffected": 13, "seriousNumAtRisk": 319, "otherNumAffected": 73, "otherNumAtRisk": 319}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 319}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Femoral hernia incarcerated", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Postoperative hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Fibroadenoma of breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Post-traumatic stress disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Urinary bladder polyp", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Breast cancer female", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Vitreous haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Hidradenitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Prostatomegaly", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 319}]}, {"term": "Lisfranc fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 319}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 17, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 26, "numAffected": 23, "numAtRisk": 319}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 25, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 24, "numAffected": 19, "numAtRisk": 319}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 12, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 24, "numAffected": 22, "numAtRisk": 319}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 324}, {"groupId": "EG001", "numEvents": 16, "numAffected": 16, "numAtRisk": 319}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com", "phone": "+46 (0)31 7761000"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-09-21", "uploadDate": "2018-08-20T07:33", "filename": "SAP_000.pdf", "size": 1881609}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-03-17", "uploadDate": "2018-08-20T07:33", "filename": "Prot_001.pdf", "size": 3088761}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic", "Germany", "Russian Federation"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Other medications", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Endoscope", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}